Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
Phase 1
Recruiting
- Conditions
- ALL, ChildhoodALLAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 15
- Registration Number
- NCT03571321
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
An Emotion-Focused Intervention for Glycemic Control in T2D
Not Applicable
Completed
- Conditions
- Type2 Diabetes
- Interventions
- Behavioral: Emotion-Focused CBT
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 20
- Registration Number
- NCT03553680
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 50
- Registration Number
- NCT03530800
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
Phase 2
Active, not recruiting
- Conditions
- Multiple MyelomaMyeloma
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 75
- Registration Number
- NCT03500445
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Medical Care, Education, Social Support, And Goal-setting to Empower Self-management for Diabetes
Not Applicable
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Other: Diabetes MESSAGES Program (second trial)Other: Diabetes MESSAGES Program
- First Posted Date
- 2018-04-04
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 265
- Registration Number
- NCT03487692
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Effects of THC on Emotional Memory Retrieval
- First Posted Date
- 2018-03-20
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 24
- Registration Number
- NCT03471585
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy
Phase 2
Terminated
- Conditions
- Head and Neck CancerHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 2
- Registration Number
- NCT03463161
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer
Phase 1
Completed
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 60
- Registration Number
- NCT03431948
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing
Phase 2
Withdrawn
- Conditions
- Oropharyngeal CancerHPV-Related Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- University of Chicago
- Registration Number
- NCT03423264
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Brexpiprazole in Borderline Personality Disorder
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 80
- Registration Number
- NCT03418675
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath